Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia? Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with ...

Acalabrutinib plus obinutuzumab shows superior long-term outcomes in treatment-naive chronic lymphocytic leukemia.

Adjuvant Docetaxel and Cyclophosphamide With or Without Epirubicin for Early Breast Cancer: Final Analysis of the Randomized DBCG 07-READ Trial First, patient-level correlation was confirmed using ...

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

A UMAP graphical depiction of 45,963 cancer cells from patients whose chronic lymphocytic leukemia has transformed into a more aggressive type. The different colors represent different cell states (e.

Cervical cancer is among the most common malignancies affecting women worldwide. In 2020 alone, approximately 600,000 women were diagnosed with this disease, and over 314,000 died from it. In 99% of ...

Blood-based biomarkers, including neutrophil-to-lymphocyte ratio and circulating tumor DNA, may improve treatment response ...

Lymphocyte-depleted Hodgkin’s lymphoma (LDHL) is a rare subtype of Hodgkin’s lymphoma, a cancer that develops in the lymphatic system. Hodgkin’s lymphoma (HL) is an uncommon cancer of the lymphatic ...

New EORTC guidelines establish meaningful change thresholds for symptom burden, physical condition/fatigue, and worries/fears in R/R CLL or SLL patients. Thresholds help identify significant ...